# Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

> **NCT00614042** · PHASE1 · COMPLETED · sponsor: **Aptevo Therapeutics** · enrollment: 96 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin's Lymphoma (NHL)

## Interventions

- **DRUG:** TRU-016 (anti-CD37 protein therapeutic)

## Key facts

- **NCT ID:** NCT00614042
- **Lead sponsor:** Aptevo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-12
- **Final completion:** 2012-03
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614042, "Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00614042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*